Coldstream Laboratories for Parental Dosage Forms NCI Contract - - BioPharm International

ADVERTISEMENT

Coldstream Laboratories for Parental Dosage Forms NCI Contract



Coldstream Laboratories, a provider of sterile drug-product development and manufacturing services, has been awarded a five-year contract with the National Cancer Institute (NCI), with the objective of developing and producing pharmaceutically acceptable parenteral dosage forms of cancer drugs for human use. Certain lead agents selected by the NCI will be assigned for development and production as parenteral products.

Coldstream Laboratories, based in Lexington, Kentucky, is a privately held CMO. It was formed in 2007 as a spin off from the University of Kentucky's Center for Pharmaceutical Sciences and Technology.

Source: Coldstream Laboratories

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here